RxDoctor Payments DataLook up a doctor →

John Botson, RPh

Rheumatology · Anchorage, AKNPI 1881700334

Payments from drug & device makers

$4,351,664in general payments, 2019–2025

Across 1,298 payments — averaging $3352.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4.1M
  • AbbVie$78K
  • Novartis$68K
  • ANI Pharmaceuticals, Inc.$34K
  • Lilly USA, LLC$24K
  • Bristol Myers Squibb$16K
  • plus $34K from 18 others
$4,864in research payments, 2019–2025

Across 1 payment — averaging $4864.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few rheumatology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$6,370,599
Medicare patients
1,188
Services billed
253,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →